Roche vs AbbVie: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Roche Holding AG (ROP.SW)

Q3 20267 Jul – 1 Oct 2026

▲2▼2

Roche Q3: Pipeline Wins, Alzheimer's Progress, But Profit Hit by Franc and Trial Halts

Alzheimer's blood test and strong data Roche reported strong Alzheimer's data and received FDA clearance for an Alzheimer's blood test, plus expanded HER2 testing. These advances could open new revenue streams in diagnostics and treatment.
New positive developments in Alzheimer's and diagnostics that could drive future growth.
Nurix deal and Phase III wins A $2.3bn Nurix deal and multiple Phase III wins, including Vabysmo's durable eye data, strengthened Roche's pipeline. Better-than-expected H1 earnings and reaffirmed guidance boosted confidence.
New partnership and clinical successes that reinforce growth prospects.
Profit drop and trial halts H1 net profit fell 6–7% due to a strong Swiss franc, and two Huntington's studies plus a partnered BioNTech cancer vaccine trial were halted. These setbacks weighed on sentiment.
New negative events that directly impacted financials and pipeline confidence.
Tariffs and competitive pressures US tariffs on EU drugs threatened margins, while competition, Medicare pricing, China pressures, and obesity-market execution remained concerns. Lilly and Novo's leadership added to the challenges.
Ongoing external and competitive risks that could limit upside.

September 202631 Aug – 1 Oct 2026

▲2▼1

Roche's pipeline surges with FDA wins and Phase III successes

Multiple Phase III wins and regulatory advances Roche reported Phase III successes in lung cancer (Tam-Peli), follicular lymphoma (Lunsumio), IgA nephropathy (sefaxersen), and obesity/diabetes (enicepatide), plus Priority Review for Enspryng in MOGAD and European label expansions for Ocrevus and Susvimo.
These pipeline wins broaden Roche's treatment portfolio and support future revenue growth.
New discovery partnerships Roche formed new discovery partnerships with Dualitas, Atavistik, and Earendil, investing in early-stage science to replenish its pipeline and access external innovation.
These deals show Roche's commitment to long-term growth through external innovation.
Competitive and pricing pressures persist Novartis competition in MS, US Medicare pricing discouraging a breast-cancer launch, and the discontinued obesity drug emugrobart weigh on Roche. China and obesity pricing/execution pressure, plus Lilly/Novo leadership, remain material risks.
These counterweights highlight ongoing challenges that could limit Roche's growth.

Latest17 Sep – 1 Oct 2026

▲3▼1

Roche's pipeline wins and new deals outweigh one obesity setback

Roche adds two new drug-discovery partnerships Roche signed collaborations with Dualitas (bispecific antibodies, up to $1 billion) and Atavistik Bio (allosteric medicines, up to $1.9 billion), plus an AI cancer-antibody deal with Earendil Labs. These add future pipeline assets at modest upfront cost, supporting long-term growth expectations.
New licensing deals expand Roche's pipeline and are a core driver of future revenue.
European approvals widen Ocrevus and Susvimo labels CHMP backed Ocrevus for children and teens with relapsing MS, and the European Commission approved Susvimo for a common cause of vision loss in older people. Both expand the patient pool for existing drugs, adding revenue in Europe.
New regulatory approvals directly expand market access and sales for Roche medicines.
Fenebrutinib and giredestrant advance toward US approval The FDA accepted Roche's fenebrutinib application for two forms of MS under priority review, and accepted giredestrant filings in breast cancer after Phase III data showed a 44% cut in progression risk. Both could become significant new products.
Late-stage regulatory filings are key milestones that can convert pipeline promise into revenue.
Roche halts obesity drug emugrobart; competition and pricing pressure persist Roche discontinued emugrobart (GYM329) for obesity, returning rights to Chugai, which hit a year-to-date low. Analysts also flag execution and pricing pressure in China and obesity, where Eli Lilly and Novo Nordisk lead. This is a real counterweight to the pipeline wins.
A pipeline failure and competitive pressure are the main negatives weighing on Roche's outlook.

13 Sep – 23 Sep 2026

▲4▼1

Roche's pipeline wins offset US pricing risk

Lung cancer drug Tam-Peli wins Phase III Roche's licensed Tam-Peli cut death risk by 54% in relapsed small-cell lung cancer, with strong survival and response gains. Roche holds worldwide rights outside China, so this supports a future growth driver and lifts confidence in its pipeline.
A major late-stage win that adds a new potential cancer treatment to Roche's pipeline.
Lunsumio combo succeeds in follicular lymphoma Lunsumio plus Revlimid met its Phase III goal in follicular lymphoma, improving progression-free survival versus standard care. This supports full approval and a broader use, strengthening Roche's blood-cancer franchise and future sales.
A confirmatory trial win that could expand an approved drug's label and revenue.
Obesity drug enicepatide hits Phase II goals Roche's once-weekly enicepatide met both goals in a mid-stage trial, cutting blood sugar and weight strongly. This advances its obesity/diabetes pipeline into Phase III, opening a large new market despite rising competition.
A key pipeline asset showing strong results in a huge potential market.
Kidney disease drug sefaxersen succeeds Genentech's sefaxersen met its Phase III goal in IgA nephropathy, sharply reducing protein in urine with best-in-class potential. This adds a promising kidney-disease treatment to Roche's late-stage pipeline, supporting future growth.
Another late-stage pipeline win that broadens Roche's potential treatment portfolio.
US Medicare pricing pressure may delay launches Roche said it may not launch a new oral breast cancer drug, citing US Medicare price alignment that cuts incentives. This regulatory risk could reduce future revenue from new medicines and shows how US pricing policy weighs on Roche's plans.
A concrete regulatory threat that could limit Roche's ability to launch and profit from new drugs.

31 Aug – 10 Sep 2026

▲3▼1

Roche's Diagnostics and Drug Pipeline Advance, Offsetting Competition

Alzheimer's Blood Test FDA Clearance FDA cleared Roche and Lilly's Elecsys pTau217 blood test for Alzheimer's, available on Roche's 4,500 US lab machines. This opens a large new testing market and strengthens Roche's diagnostics leadership, supporting future revenue growth.
This is a new regulatory win that expands Roche's diagnostics franchise and addresses a major unmet need.
Enspryng Priority Review for MOGAD FDA granted Priority Review to Roche's Enspryng for MOGAD, a rare autoimmune disease with no approved treatments. If approved, it would be first-in-class, adding a new growth driver and reinforcing Roche's neuroscience portfolio.
This is a new regulatory milestone that could lead to a first-in-class therapy and new sales.
Blood-Cancer Deal with Simcere Roche committed $75 million upfront for global rights to Simcere's experimental blood-cancer drug SIM0660, in a deal worth up to $1.53 billion. The low upfront cost limits risk while adding a potential future pipeline asset.
This is a new business development move that expands Roche's oncology pipeline with limited near-term financial risk.
Novartis Competition in MS Novartis's remibrutinib showed positive Phase 3 results in multiple sclerosis, with analysts estimating $3 billion in peak sales. This could challenge Roche's BTK inhibitor in MS, creating competitive pressure on future sales.
This is a new competitive threat that could limit Roche's market share in multiple sclerosis.

August 202612 Aug – 28 Aug 2026

▲3▼1

Roche's diagnostics win big; cancer vaccine setback offsets

Alzheimer's blood test cleared by FDA Roche won FDA clearance for the first blood test that helps diagnose Alzheimer's amyloid buildup, usable on its 4,500 US lab machines. This opens a large new testing market and strengthens Roche's diagnostics leadership, a clear positive for future revenue.
It is the period's biggest new approval and a first-of-its-kind product, directly lifting Roche's growth outlook.
HER2 cancer tests approved for wider use FDA expanded approval of Roche's HER2 companion tests to guide treatment in gastroesophageal cancer, a hard-to-treat disease with no prior approved test. This widens the patient pool for Roche's diagnostics and supports its personalized-medicine franchise.
A new regulatory win that broadens Roche's diagnostic portfolio and adds revenue potential.
Vabysmo shows strong two-year eye data Roche's Vabysmo kept improving vision and retinal health in a severe eye disease over two years, with most patients needing treatment only every 20 weeks. Longer dosing intervals make the drug more attractive versus rivals, supporting sales growth.
New clinical data strengthens the case for a key Roche drug and its competitive position.
Partnered cancer vaccine trial halted BioNTech stopped a mid-stage trial of an mRNA cancer vaccine developed with Roche after a safety board saw worse survival in one arm. This removes a hoped-for pipeline win and dents confidence in Roche's cancer vaccine bet.
It is the period's main negative, a real counterweight to the diagnostic wins.

12 Aug – 28 Aug 2026

▲3▼1

Roche's diagnostics win big; cancer vaccine setback offsets

Alzheimer's blood test cleared by FDA Roche won FDA clearance for the first blood test that helps diagnose Alzheimer's amyloid buildup, usable on its 4,500 US lab machines. This opens a large new testing market and strengthens Roche's diagnostics leadership, a clear positive for future revenue.
It is the period's biggest new approval and a first-of-its-kind product, directly lifting Roche's growth outlook.
HER2 cancer tests approved for wider use FDA expanded approval of Roche's HER2 companion tests to guide treatment in gastroesophageal cancer, a hard-to-treat disease with no prior approved test. This widens the patient pool for Roche's diagnostics and supports its personalized-medicine franchise.
A new regulatory win that broadens Roche's diagnostic portfolio and adds revenue potential.
Vabysmo shows strong two-year eye data Roche's Vabysmo kept improving vision and retinal health in a severe eye disease over two years, with most patients needing treatment only every 20 weeks. Longer dosing intervals make the drug more attractive versus rivals, supporting sales growth.
New clinical data strengthens the case for a key Roche drug and its competitive position.
Partnered cancer vaccine trial halted BioNTech stopped a mid-stage trial of an mRNA cancer vaccine developed with Roche after a safety board saw worse survival in one arm. This removes a hoped-for pipeline win and dents confidence in Roche's cancer vaccine bet.
It is the period's main negative, a real counterweight to the diagnostic wins.

July 20267 Jul – 5 Aug 2026

▲3▼1

Roche gains on pipeline wins and earnings despite profit dip and tariffs

Pipeline and diagnostic advances Roche reported positive Alzheimer's data, progress on a blood test, a new TB test, a lupus submission, FDA priority review for Gazyva, and EU backing for Susvimo. These advances support future sales growth.
These pipeline and diagnostic wins were key positive drivers during the period.
Nurix deal and analyst support Roche agreed to a $2.3bn deal with Nurix for blood-cancer drugs, and UBS favored Roche over AI. The deal expands the pipeline, while analyst backing boosted investor confidence.
The Nurix acquisition and UBS preference were notable positive developments.
Earnings beat and reaffirmed guidance Shares jumped 5% after Roche reaffirmed guidance and reported better-than-expected H1 earnings, helped by a lower generic-loss forecast. This reassured investors about the company's outlook.
The earnings beat and guidance reaffirmation directly lifted the stock.
Profit dip, study halts, competition, tariffs H1 net profit fell 6–7% on the strong franc; two Huntington's studies were discontinued; Outlook Therapeutics' Lytenava approval adds eye-disease competition; and new US tariffs on EU drugs threaten exports and margins.
These setbacks weighed on sentiment and pose risks to future performance.

26 Jul – 5 Aug 2026

▲3▼1

Roche gains on outlook, drug wins, but tariffs and competition weigh

Roche reiterates 2026 outlook, shares jump 5% Roche reaffirmed its full-year guidance, reassuring investors and sending shares up about 5%. This signals confidence in future earnings and reduces uncertainty, supporting the stock price.
This is the biggest single-day move and directly answers why the stock moved.
New US tariffs on EU drugs threaten Roche's exports Trump announced phased tariffs on generic drug imports, with rates up to 200% by 2029, and new 10-12.5% tariffs on EU goods including pharmaceuticals. As a major EU drug exporter, Roche faces higher costs and potential sales pressure, a negative for the stock.
This is a new, material risk that could hurt Roche's US sales and profitability.
Roche wins FDA clearance for diagnostic and EU backing for eye implant Roche received FDA clearance for its cobas BV/CV assay and EU recommendation for Susvimo eye implant. These expand its diagnostics and treatment offerings, adding future revenue streams and strengthening its pipeline.
New approvals directly support future sales growth and pipeline strength.
Nurix and Labcorp advances boost Roche's pipeline and diagnostics Nurix enrolled the first patient in a Phase 3 trial of bexobrutideg with Roche, and Labcorp launched Roche's PTEN companion diagnostic nationwide. These advances validate Roche's collaboration strategy and expand its diagnostic reach, supporting long-term growth.
These are new positive developments that show pipeline and diagnostic progress.

14 Jul – 24 Jul 2026

▲2▼1

Roche's H1 profit falls on franc, but pipeline and diagnostics advance

Strong Swiss franc cuts reported H1 profit Roche's first-half net profit fell 6-7% to about 6.9-7.3 billion francs, mainly because the strong Swiss franc reduced the value of overseas sales. This headline weakness can pressure the stock, even though sales rose 6% in constant currency.
This is the main negative force this period, explaining why reported earnings look weak.
Lower generic hit and better-than-expected earnings lift shares Roche cut its expected 2026 generic sales loss to about 600 million francs from 1 billion, and first-half earnings beat expectations. Shares jumped 3.2% as investors saw less near-term revenue erosion, though full-year guidance was unchanged.
This is the key positive surprise that drove the stock up on results day.
New drug and diagnostic approvals expand future sales Roche won FDA priority review for Gazyva in a kidney disease, CHMP backing for Susvimo eye implant in Europe, and FDA clearance for a new vaginitis test. These add future revenue streams and strengthen its pipeline and diagnostics franchise.
These regulatory wins are new and support long-term growth, a core part of the investment case.
Nurix deal closes, but new eye competition emerges Roche closed its $2.3 billion Nurix collaboration for a blood cancer drug, gaining a promising asset. However, FDA approval of Outlook Therapeutics' Lytenava creates new competition for Roche's Avastin in eye disease, a modest negative.
This shows both pipeline progress and a competitive threat, giving a balanced view.

7 Jul – 10 Jul 2026

▲3

Roche advances Alzheimer's, TB, lupus and AI, but Huntington's setback

Alzheimer's data and blood test progress Roche will present long-term trontinemab data and pTau217 blood test results at AAIC 2026, including a Phase III prevention study design. Positive data could boost confidence in its Alzheimer's pipeline and diagnostics, supporting future sales.
This is new and shows pipeline progress that can drive future revenue.
UBS backs Roche as safer bet than AI UBS reiterated overweight on European pharma, preferring Roche among large caps due to improving earnings and low valuations. This can attract more investors, pushing the stock up.
New analyst endorsement highlights a shift in capital flows toward Roche.
New TB test and lupus drug submission Roche received CE Mark for an automated TB test and has submitted obinutuzumab for lupus with FDA decision expected by December 2026. These expand diagnostics and treatment offerings, adding revenue potential.
New product approvals and regulatory milestones support growth.
Nurix deal adds pipeline, but Huntington's failure Roche signed a $2.3 billion deal with Nurix for a promising blood cancer drug, but discontinued two Huntington's disease studies. The deal strengthens the pipeline, while the setback removes a potential therapy, balancing the impact.
Both a positive pipeline boost and a negative clinical setback occurred this period.

Q2 202618 Jun – 2 Jul 2026

▲4

Roche's pipeline and diagnostics surge with FDA wins and new products

FDA accepts Lunsumio-Polivy combo filing FDA accepted Roche's filing for a chemotherapy-free lymphoma combo that cut progression risk by 59%. If approved, it opens a new treatment option in a hard-to-treat cancer, supporting future sales growth.
New regulatory milestone that expands Roche's oncology portfolio and potential revenue.
FDA priority review for Enspryng in thyroid eye disease FDA granted priority review for Enspryng as a first at-home treatment for thyroid eye disease, with a decision due October 2026. This could add a new indication to an existing drug, boosting its sales potential.
New regulatory catalyst that could broaden an approved drug's label and revenue.
Roche launches AXELIOS 1 gene sequencer, undercutting Illumina Roche launched its own next-generation sequencing platform at $750,000, below Illumina's machines. This challenges Illumina's 70% market share and opens a new growth avenue in the $7.3 billion sequencing market.
New product launch that enters a large, fast-growing market and pressures a key competitor.
Divarasib beats approved KRAS inhibitors in Phase III Genentech's divarasib showed better progression-free and overall survival than current KRAS G12C drugs in lung cancer. Positive late-stage data raise the odds of a new blockbuster and strengthen Roche's pipeline.
New clinical win that could lead to a best-in-class cancer drug and future revenue.

June 202618 Jun – 2 Jul 2026

▲4

Roche's pipeline and diagnostics surge with FDA wins and new products

FDA accepts Lunsumio-Polivy combo filing FDA accepted Roche's filing for a chemotherapy-free lymphoma combo that cut progression risk by 59%. If approved, it opens a new treatment option in a hard-to-treat cancer, supporting future sales growth.
New regulatory milestone that expands Roche's oncology portfolio and potential revenue.
FDA priority review for Enspryng in thyroid eye disease FDA granted priority review for Enspryng as a first at-home treatment for thyroid eye disease, with a decision due October 2026. This could add a new indication to an existing drug, boosting its sales potential.
New regulatory catalyst that could broaden an approved drug's label and revenue.
Roche launches AXELIOS 1 gene sequencer, undercutting Illumina Roche launched its own next-generation sequencing platform at $750,000, below Illumina's machines. This challenges Illumina's 70% market share and opens a new growth avenue in the $7.3 billion sequencing market.
New product launch that enters a large, fast-growing market and pressures a key competitor.
Divarasib beats approved KRAS inhibitors in Phase III Genentech's divarasib showed better progression-free and overall survival than current KRAS G12C drugs in lung cancer. Positive late-stage data raise the odds of a new blockbuster and strengthen Roche's pipeline.
New clinical win that could lead to a best-in-class cancer drug and future revenue.

18 Jun – 2 Jul 2026

▲4

Roche's pipeline and diagnostics surge with FDA wins and new products

FDA accepts Lunsumio-Polivy combo filing FDA accepted Roche's filing for a chemotherapy-free lymphoma combo that cut progression risk by 59%. If approved, it opens a new treatment option in a hard-to-treat cancer, supporting future sales growth.
New regulatory milestone that expands Roche's oncology portfolio and potential revenue.
FDA priority review for Enspryng in thyroid eye disease FDA granted priority review for Enspryng as a first at-home treatment for thyroid eye disease, with a decision due October 2026. This could add a new indication to an existing drug, boosting its sales potential.
New regulatory catalyst that could broaden an approved drug's label and revenue.
Roche launches AXELIOS 1 gene sequencer, undercutting Illumina Roche launched its own next-generation sequencing platform at $750,000, below Illumina's machines. This challenges Illumina's 70% market share and opens a new growth avenue in the $7.3 billion sequencing market.
New product launch that enters a large, fast-growing market and pressures a key competitor.
Divarasib beats approved KRAS inhibitors in Phase III Genentech's divarasib showed better progression-free and overall survival than current KRAS G12C drugs in lung cancer. Positive late-stage data raise the odds of a new blockbuster and strengthen Roche's pipeline.
New clinical win that could lead to a best-in-class cancer drug and future revenue.

AbbVie Inc (ABBV)

Q3 20266 Jul – 1 Oct 2026

▲2▼2

AbbVie Q3: Earnings Beat, Pipeline Wins, But Pricing and Trial Setbacks

Strong Q2 Earnings and Raised Guidance AbbVie's Q2 EPS and revenue beat estimates, and the company raised full-year revenue guidance. Skyrizi and Rinvoq now make up over 47% of revenue, offsetting Humira's decline. Neuroscience guidance also increased to about $12.7 billion.
This shows the core business outperformed and management is optimistic about future growth.
Pipeline Progress and New Approvals AbbVie reported Phase 3 successes, received EU approvals, and gained FDA approval for JUVMO. These advances strengthen the company's drug portfolio and future revenue potential.
New drug approvals and trial wins are key drivers of long-term growth and investor confidence.
EPCORE DLBCL-1 Trial Miss and Guidance Cut The EPCORE DLBCL-1 trial missed its endpoint, leading AbbVie to cut profit guidance. The stock dropped 4% on the news, highlighting pipeline risks.
This was a major setback that directly hurt earnings expectations and investor sentiment.
Pricing Pressures and Competitive Threats Trump demanded U.S. price cuts, and J&J's oral psoriasis pill won Chinese approval. Apogee's $10.9 billion acquisition will dilute earnings until 2032, and oncology sales fell 2.8% as Imbruvica dropped 27.1%.
These factors create headwinds for revenue and profitability, weighing on the stock.

September 20263 Sep – 1 Oct 2026

▲2▼2

AbbVie's Pipeline Wins Offset Apogee Dilution and Oncology Decline

Pipeline Momentum AbbVie reported multiple Phase 3 wins: etentamig for myeloma, Qulipta for menstrual migraine, and RINVOQ for vitiligo. EU approved Rinvoq for juvenile arthritis, and the FDA approved JUVMO for Parkinson's. Early-stage data for zumilokibart and ABBV-295 also showed promise.
These pipeline successes signal future growth and strengthen AbbVie's competitive position.
Neuroscience Guidance Raised AbbVie raised its neuroscience revenue guidance to about $12.7 billion, with total revenue near $67.6 billion. This reflects confidence in its neuroscience portfolio and overall business strength.
Higher guidance indicates management's optimism and potential for earnings growth.
Apogee Acquisition Dilutes Earnings The $10.9 billion Apogee acquisition will reduce earnings by $0.14 per share in 2026 and $0.46 in 2027, with profits not expected until 2032. This near-term dilution pressures the stock.
The acquisition's dilution is a significant near-term headwind for earnings per share.
Oncology Sales Decline Oncology sales fell 2.8% as Imbruvica dropped 27.1% due to competition and IRA pricing. Newer drugs did not fully offset the decline, highlighting challenges in this segment.
The decline in oncology revenue weighs on overall growth and profitability.

Latest26 Sep – 1 Oct 2026

▲4

AbbVie's pipeline wins and new drug approvals drive growth outlook

FDA approves JUVMO for Parkinson's disease The FDA approved JUVMO (tavapadon), the first selective D1/D5 agonist for Parkinson's, with U.S. launch set for October 2026. This adds a differentiated neuroscience drug to AbbVie's portfolio, supporting future revenue growth and lifting investor confidence.
A major new drug approval directly expands AbbVie's revenue base and pipeline strength.
Zumilokibart succeeds in Phase 2 atopic dermatitis trial AbbVie's zumilokibart met the main goal in a Phase 2 study for atopic dermatitis, and the mid-dose will move into final-stage testing. This strengthens the immunology pipeline and offers a potential new treatment for a common skin condition, supporting long-term growth.
Positive mid-stage trial results advance a key pipeline candidate, signaling future revenue potential.
ABBV-295 shows promising weight loss and long half-life Phase 1 data for ABBV-295 showed up to 9.8% weight loss and an 11-12 day half-life, supporting less frequent dosing. This opens a new market for AbbVie in obesity care, a high-growth area, and could become a significant future sales driver.
Early data support a potential best-in-class obesity drug, a major new growth opportunity.
RINVOQ shows sustained vitiligo repigmentation in Phase 3 Phase 3 data show RINVOQ produced continued skin repigmentation in vitiligo through 76 weeks with no new safety issues. This supports a potential new use for a key drug, expanding its label and adding a new revenue stream if approved.
Late-stage data support a new indication for a major drug, enhancing its growth prospects.

19 Sep – 24 Sep 2026

▲3▼1

AbbVie's pipeline and label wins offset oncology and pricing headwinds

Qulipta hits Phase 3 goal in menstrual migraine Qulipta met the main goal and all secondary goals in a late-stage trial for menstrual migraine, a condition with no approved treatment. If approved, it opens a new market of over nine million U.S. patients, adding a fresh sales driver and supporting the stock.
New clinical win expands a fast-growing drug into an untapped market, a clear positive for future revenue.
Rinvoq wins EU approval for juvenile arthritis European regulators approved Rinvoq for polyarticular juvenile idiopathic arthritis, its 11th EU use. This widens the label of a key growth drug already on track for about $10.2 billion in 2026 sales, reinforcing confidence in AbbVie's immunology growth.
New regulatory approval directly expands a major growth drug's market and supports the bull case.
AI drug-discovery deals and EPKINLY approval AbbVie signed multi-year AI collaborations with Iambic and joined the AISB Bind network to speed up drug discovery, and Health Canada approved EPKINLY for relapsed follicular lymphoma. These broaden the pipeline and add a new approved use, supporting long-term growth.
New partnerships and a new approval show pipeline expansion and fresh revenue potential.
Oncology sales fall on Imbruvica and IRA pricing First-half oncology sales dropped 2.8% to $3.28 billion as Imbruvica fell 27.1% on competition and Medicare drug-price changes. Newer drugs like Venclexta and Elahere grew but did not fully offset the decline, weighing on overall growth.
A real counterweight: a key segment is shrinking due to competition and pricing pressure.

3 Sep – 17 Sep 2026

▲3▼1

AbbVie's pipeline and guidance wins offset Apogee dilution

Apogee acquisition dilutes near-term earnings AbbVie closed its $10.9 billion purchase of Apogee Therapeutics, adding an experimental immunology drug but cutting adjusted earnings by $0.14 per share in 2026 and $0.46 in 2027. Profit won't get a boost until 2032, so near-term investors see lower earnings and the stock faces pressure.
This is the main new negative event this period and directly lowers reported earnings, a key driver of the stock price.
Etentamig succeeds in Phase 3 myeloma trial AbbVie's experimental blood-cancer drug etentamig met both main goals in a late-stage trial, with a 74% response rate versus 46% for standard care and a 60% lower risk of disease worsening. This strengthens the oncology pipeline and raises hopes for a new growth driver, supporting the stock.
This is a major new clinical win that expands AbbVie's cancer franchise and improves long-term growth prospects.
Qulipta succeeds in menstrual migraine trial AbbVie's migraine drug Qulipta hit the main goal in a Phase 3 trial for menstrual migraine, reducing migraine days with a convenient dosing schedule. Qulipta sales already grew 31% to $350 million last quarter, so a new use could add revenue and lift the stock.
This is a new positive trial result that could expand the label and sales of an already fast-growing drug.
Neuroscience outlook raised on broad growth AbbVie lifted its 2026 neuroscience revenue forecast to about $12.7 billion and total revenue to roughly $67.6 billion, after first-half neuroscience sales jumped 21.8%. Strong demand across Vraylar, Botox, Qulipta, Ubrelvy and Vyalev gives investors more confidence in future profits, pushing the stock up.
This is a new guidance raise that directly improves revenue expectations and signals broad-based demand strength.

August 20261 Aug – 28 Aug 2026

▲3▼2

AbbVie's Skyrizi-Rinvoq Momentum Outweighs Pricing and Competition Risks

Skyrizi and Rinvoq Now Over 47% of Revenue AbbVie's two newer drugs, Skyrizi and Rinvoq, now make up more than 47% of total revenue and are expected to top $31 billion this year, more than offsetting declining sales of older Humira.
This shows the core growth engine replacing Humira, a key positive force for the stock.
Neuroscience Guidance Raised and Pipeline Advances AbbVie raised its neuroscience revenue guidance to about $12.7 billion, and reported promising lung cancer data plus a European filing for a subcutaneous version of Skyrizi for Crohn's disease, strengthening future growth prospects.
These pipeline and guidance updates point to new sources of revenue and expanded use of existing drugs.
Citadel Hedge Fund Boosts Stake 547% Citadel, a major hedge fund, increased its ownership stake in AbbVie by 547%, a sign that some large investors see strong value in the company despite recent concerns.
A big institutional buyer can lift sentiment and signal confidence in the stock.
Trump Demands U.S. Price Cuts Within 60 Days President Trump demanded that AbbVie cut U.S. drug prices within 60 days, threatening its pricing power and adding regulatory uncertainty that could pressure revenue and profit margins.
This is a new political risk that directly challenges AbbVie's ability to set prices in its largest market.
J&J's Oral Psoriasis Pill Wins Chinese Approval Johnson & Johnson's oral psoriasis pill Icotyde received approval in China, where 8.4 million patients could switch from injectable treatments like AbbVie's Skyrizi, posing a competitive threat in a key growth market.
This new competition could slow Skyrizi's expansion and take market share.

19 Aug – 28 Aug 2026

▲3▼1

AbbVie's pipeline and franchise expansion offset profit-guidance cut

Citadel boosts AbbVie stake by 547% Ken Griffin's Citadel bought 2.68 million more ABBV shares, a 547% increase, at an average of $214.90. A major fund raising its bet signals confidence in AbbVie's long-term value and can draw other investors in, supporting the stock price.
Large institutional buying is a fresh, concrete signal of confidence that can lift investor sentiment and demand for the shares.
New lung cancer data strengthens oncology pipeline AbbVie presented promising early data for several experimental lung cancer drugs at a major conference, with high response rates and manageable side effects. This broadens its pipeline beyond immunology and neuroscience, giving investors another potential growth engine and supporting the stock.
Fresh clinical progress on multiple oncology programs adds a new growth pillar, which can improve the long-term earnings outlook.
Skyrizi submitted for easier Crohn's dosing in Europe AbbVie asked European regulators to approve Skyrizi as a subcutaneous (under-the-skin) induction treatment for Crohn's disease, based on positive trial data. If approved, it offers patients a more convenient option and extends Skyrizi's reach, supporting future sales and the stock.
A regulatory filing that could widen a key drug's use is a concrete pipeline expansion, not just a repeat of past results.
J&J's oral psoriasis pill approved in China Johnson & Johnson won Chinese approval for Icotyde, a once-daily pill for plaque psoriasis, a market with over 8.4 million patients where AbbVie's Skyrizi competes. A convenient oral option could take share from injectables like Skyrizi, weighing on AbbVie's growth prospects in China.
This is a new competitive threat in a large market that could pressure sales of a key AbbVie drug.

1 Aug – 14 Aug 2026

▲2▼2

AbbVie's core drugs stay strong, but pricing pressure and pipeline setback weigh

Trump demands drug price cuts President Trump sent letters to major drugmakers, including AbbVie, demanding U.S. prescription price cuts within 60 days. This threatens future pricing power and revenue, pushing the stock down as investors worry about lower profits.
This is a new regulatory threat that directly pressures AbbVie's pricing and future earnings.
Skyrizi and Rinvoq fuel growth AbbVie's newer immunology drugs Skyrizi and Rinvoq now make up over 47% of total revenue, with combined sales expected to exceed $31 billion this year. Their rapid growth is replacing declining Humira sales and supports the stock's long-term value.
This shows the core business is successfully transitioning beyond Humira, a key driver of future revenue.
Neuroscience outlook raised AbbVie raised its 2026 neuroscience revenue forecast to about $12.7 billion, driven by strong sales of Vraylar, migraine drugs Ubrelvy and Qulipta, and Botox Therapeutic. This diversification adds a growing revenue stream and boosts investor confidence.
This is a new positive update showing another part of AbbVie's business is performing well and raising guidance.
Epcoritamab trial fails survival goal Genmab and AbbVie confirmed that the Phase 3 trial of epcoritamab for a type of lymphoma did not meet its main overall survival goal. This pipeline setback could delay or reduce the drug's potential, weighing on sentiment.
This is a new negative pipeline event that could hurt future oncology revenue prospects.

July 20266 Jul – 31 Jul 2026

▲3▼1

AbbVie's Q2 Beat and EU Approvals Offset by Trial Miss and Profit Guidance Cut

EU Approvals Expand Drug Labels AbbVie won European approvals for TEPKINLY in follicular lymphoma, Boey for frown lines, and RINVOQ for alopecia areata, broadening its oncology, aesthetics, and immunology offerings. These label expansions can drive future revenue growth.
New approvals are a key positive development that can boost investor confidence and future sales.
Q2 Earnings Beat and Guidance Raise AbbVie reported Q2 EPS of $3.65 and revenue of $16.99 billion, beating estimates. Management raised full-year revenue guidance by $300 million, citing strong growth in Skyrizi, Rinvoq, and neuroscience.
The earnings beat and guidance raise show operational strength and support the bull case.
Voluntary Pricing Deals Reduce Uncertainty AbbVie entered voluntary most-favored-nation pricing agreements, which lessen regulatory uncertainty around drug pricing. This proactive step may stabilize the pricing environment and reduce political risk.
Reduced regulatory uncertainty is a positive for the stock as it removes a potential overhang.
Trial Miss and Profit Guidance Cut The Phase 3 EPCORE DLBCL-1 trial for epcoritamab missed its overall survival endpoint, hurting oncology sentiment. Additionally, a $291 million acquired IPR&D charge led AbbVie to cut full-year adjusted earnings guidance, sending shares down 4%.
The trial failure and earnings guidance cut are significant negatives that pressured the stock.

25 Jul – 31 Jul 2026

▲2▼2

AbbVie beats Q2, raises revenue outlook, but full-year profit guidance cut

Q2 beat and raised revenue guidance AbbVie beat Q2 estimates with $3.65 EPS and $16.99B revenue, and raised full-year revenue guidance by $300M on strong Skyrizi, Rinvoq and neuroscience growth. This shows the core business is performing well, supporting the stock's long-term value.
This is the main new positive event this period, directly driving the stock's fundamental outlook.
Full-year profit guidance lowered Despite the revenue beat, AbbVie cut its full-year adjusted earnings outlook, partly due to a $291M charge for acquired IPR&D and milestone expenses. This disappointed investors and caused shares to fall 4%, as it signals near-term profit pressure.
This is the key negative event this period, explaining the immediate stock drop and investor concern.
EU approval of RINVOQ for alopecia areata AbbVie won European approval for RINVOQ in severe alopecia areata, expanding its immunology franchise. This adds a new revenue stream and reinforces RINVOQ's growth potential, which is positive for the stock.
This is a new regulatory win that expands the market for a key drug, supporting future sales.
Epcoritamab trial setback The Phase 3 EPCORE DLBCL-1 trial for epcoritamab missed its overall survival endpoint in the U.S., a setback for AbbVie's oncology pipeline. This could delay or reduce the drug's potential, weighing on sentiment.
This is a new negative pipeline event that affects future growth prospects.

6 Jul – 23 Jul 2026

▲3▼1

AbbVie's pipeline wins approvals but faces trial setback and new competition

EU approval of TEPKINLY for follicular lymphoma The European Commission approved AbbVie's TEPKINLY combination for relapsed follicular lymphoma, a chemotherapy-free option that cut progression risk by 79%. This expands AbbVie's oncology portfolio and adds a new revenue stream, supporting long-term growth.
New approval directly boosts AbbVie's oncology franchise and future sales.
EU approval of Boey for frown lines Allergan Aesthetics, part of AbbVie, won EU approval for Boey, a fast-acting botulinum toxin for frown lines. This strengthens AbbVie's aesthetics business and offers a new treatment option, potentially driving revenue growth.
New product approval expands AbbVie's aesthetics portfolio and revenue potential.
Voluntary drug-pricing deals with Trump administration AbbVie agreed to voluntary most-favored-nation pricing with the Trump administration. While this may lower prices for some drugs, AbbVie's newer immunology drugs Skyrizi and Rinvoq are expected to offset Humira's decline, and the deal reduces regulatory uncertainty.
New pricing agreement affects AbbVie's revenue but is manageable given strong new drugs.
Epcoritamab trial misses overall survival endpoint Genmab and AbbVie confirmed that the Phase 3 EPCORE DLBCL-1 trial did not meet its primary overall survival endpoint in the U.S. This setback could delay or reduce the drug's potential in this indication, weighing on sentiment.
New negative trial result directly impacts AbbVie's oncology pipeline and investor confidence.

Q2 202617 Jun – 3 Jul 2026

▲2▼2

AbbVie's $10.9B Apogee Deal and Drug Wins Lift Shares to 52-Week High

Apogee Acquisition AbbVie agreed to buy Apogee Therapeutics for $10.9 billion in cash, gaining a potential rival to Dupixent. The deal is funded from operating cash flow, so no new debt is needed.
This major acquisition is a key new event that could drive future growth and investor sentiment.
Drug Label Expansions and Phase 3 Wins AbbVie expanded the labels for Skyrizi and Rinvoq and reported positive Phase 3 results. This pushed the stock to a 52-week high and added $43 billion in market value.
These clinical and regulatory successes directly boosted the stock price and market value.
Congressional Probe into China Trials A bipartisan congressional probe into AbbVie's China clinical trials could raise compliance costs and delay drug pipelines. This adds uncertainty and potential headwinds for the company.
This regulatory risk is a new negative factor that could weigh on the stock.
Decelerating Growth of Key Drugs Growth of key drugs Skyrizi and Rinvoq is slowing, which could pressure the stock's rich valuation. Investors may worry about future revenue growth.
Slowing growth is a fundamental concern that could limit upside for the stock.

June 202617 Jun – 3 Jul 2026

▲2▼2

AbbVie's $10.9B Apogee Deal and Drug Wins Lift Shares to 52-Week High

Apogee Acquisition AbbVie agreed to buy Apogee Therapeutics for $10.9 billion in cash, gaining a potential rival to Dupixent. The deal is funded from operating cash flow, so no new debt is needed.
This major acquisition is a key new event that could drive future growth and investor sentiment.
Drug Label Expansions and Phase 3 Wins AbbVie expanded the labels for Skyrizi and Rinvoq and reported positive Phase 3 results. This pushed the stock to a 52-week high and added $43 billion in market value.
These clinical and regulatory successes directly boosted the stock price and market value.
Congressional Probe into China Trials A bipartisan congressional probe into AbbVie's China clinical trials could raise compliance costs and delay drug pipelines. This adds uncertainty and potential headwinds for the company.
This regulatory risk is a new negative factor that could weigh on the stock.
Decelerating Growth of Key Drugs Growth of key drugs Skyrizi and Rinvoq is slowing, which could pressure the stock's rich valuation. Investors may worry about future revenue growth.
Slowing growth is a fundamental concern that could limit upside for the stock.

17 Jun – 3 Jul 2026

▲2▼2

AbbVie hits 52-week high on Apogee deal and drug approvals, but China probe and slowing drug growth weigh

Apogee acquisition and expanded drug labels drive record high AbbVie agreed to buy Apogee Therapeutics for $10.9 billion, adding a promising immunology drug. It also won approvals to expand Skyrizi and Rinvoq to new patient groups. These moves strengthen future growth and pushed the stock to a 52-week high, adding $43 billion in market value in a week.
This is the main reason the stock hit a new high and reflects the biggest new development this period.
US Congress opens bipartisan probe into AbbVie's China clinical trials A House committee is investigating AbbVie's clinical trials in China, including sites linked to the Chinese military and in Xinjiang. While no illegal conduct is alleged, the probe could lead to tighter oversight, higher compliance costs, and restrictions on trial locations, potentially delaying drug pipelines and hurting the stock.
This is a new risk that could negatively affect the stock and was not in earlier reports.
Growth of key drugs Skyrizi and Rinvoq shows signs of slowing Skyrizi's growth decelerated to 29.2% from 31.9%, and Rinvoq's growth slowed to 20.2% from 28.6%. These drugs are critical to AbbVie's post-Humira strategy, and any sustained slowdown could pressure the stock's valuation, which already prices in high growth.
This is a new concern about the company's growth engine that could weigh on the stock.
Positive late-stage trial results and new drug approvals bolster pipeline AbbVie reported positive Phase 3 data for venetoclax in leukemia and epcoritamab in lymphoma, and won approvals for MAVIRET in hepatitis C, SKYRIZI in pediatric psoriasis, and a new neurotoxin Boey. These advances strengthen the company's oncology and aesthetics portfolios, supporting long-term revenue growth.
These are new clinical and regulatory wins that reinforce AbbVie's pipeline and future sales potential.

20 Jun – 25 Jun 2026

▲3

AbbVie's $10.9B Apogee buy expands immunology pipeline

Apogee acquisition adds promising immunology drug AbbVie agreed to buy Apogee Therapeutics for $10.9 billion in cash, gaining zumilokibart, a potential rival to Dupixent for eczema and asthma. The deal strengthens AbbVie's immunology franchise and pipeline, which investors view as a positive for long-term growth.
This is the main new event driving ABBV's stock and future prospects.
Deal funded without debt, preserving financial flexibility AbbVie will pay for Apogee entirely from operating cash flow, avoiding new debt. This keeps its balance sheet strong and reduces financial risk, which supports the stock price.
Shows the acquisition is financially manageable and not a strain.
Near-term earnings dilution, but long-term growth The deal won't add to adjusted earnings per share until 2032, so it may slightly weigh on near-term profits. However, it positions AbbVie for future growth in immunology, balancing the short-term cost with long-term benefit.
Highlights the trade-off investors are weighing.
Analysts see reasonable premium and strategic fit Citi and other analysts said the 49% premium is not excessive given Apogee's strong data and scarce immunology assets. The deal also fits with AbbVie's existing commercial infrastructure, supporting a positive view.
Analyst validation reinforces the market's positive reaction.